|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Indication | Esophageal cancer | Esophagogastric junction cancer | Gastric cancer | Head and neck squamous cell carcinoma | Non-small cell lung cancer | Melanoma | Ovarian cancer | Urothelial cancer | Synovial sarcoma and myxoid/round cell  liposarcoma |
| HLA screened (N) | 284 | 228 | 271 | 601 | 3189 | 668 | 539 | 270 | 118 |
| HLA eligible (%) | 46 | 45 | 43 | 42 | 43 | 50 | 49 | 43 | 55 |
| MAGE-A4  evaluable (N) | 104 | 91 | 73 | 200 | 457 | 245 | 225 | 93 | 61 |
| MAGE-A4  positive (%) | 22 | 25 | 8 | 22 | 14 | 16 | 24 | 32 | 54 |
| HLA, human leukocyte antigen; MAGE-A4, melanoma-associated antigen A4. | | | | | | | | | |

**Table.** HLA eligibility and MAGE-A4 prevalence in a screening protocol (NCT02636855)